Johnson & Johnson reports $25.4 billion Q3 sales

• Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 sales of $25.4 billion, representing 5.9% growth year over year and raising its full-year guidance.
• The company reported adjusted earnings per share of $2.59, while GAAP EPS of $0.09 reflected special charges related to litigation and acquisitions.
• Johnson & Johnson increased its 2026 guidance, expecting reported sales of approximately $101.2 billion and adjusted EPS of $11.10.

Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 results with sales increasing 5.9% to $25.4 billion, supported by operational growth of 6.0% and adjusted operational growth of 6.1%.

The company said third-quarter GAAP earnings per share of $0.09 included a one-time special charge related to the proposed talc litigation resolution, the acquisition of Firefly Bio, and a strategic collaboration with Sail Biomedicines.

Johnson & Johnson reported adjusted EPS of $2.59, which also reflected the impact of the Firefly Bio acquisition and Sail Biomedicines collaboration, while increasing its full-year 2026 adjusted EPS guidance by $0.06.

The company highlighted recent product developments, including market authorization for OTTAVA, a table-integrated soft tissue robotic system, approval of IMAAVY for warm autoimmune hemolytic anemia, and priority review for RYBREVANT FASPRO in advanced head and neck cancer.

Johnson & Johnson operates pharmaceutical, medical technology, and healthcare businesses globally, with products and research programs across multiple therapeutic areas.